Kura Oncology's (KURA) ziftomenib shows AML promise amid competition. See why I'm inclined to view the current price levels ...

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC ...

FORWARD-53 is an ongoing Phase 2 open-label trial of WVE-N531. Muscle biopsies are taken after 24 and 48 weeks of dosing. The primary endpoint is dystrophin protein levels, and the trial is also ...

Spyre Therapeutics' innovative combination therapy approach targets multiple inflammatory pathways. Learn why SYRE stock is a Buy.

With this circuit, CEA-Leti demonstrated 4- and 16-point QAM, that increases the possible number of multiplexed devices by ...

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

An announcement from Repare Therapeutics ( ($RPTX) ) is now available. Repare Therapeutics has announced a significant restructuring, reducing its ...

Our recently implemented re-structuring and the re-prioritization of our clinical portfolio meaningfully extends our cash runway into late ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...

H.C. Wainwright raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $70 from $69 and keeps a Buy rating on the shares following ...

Typically, you might invoke Task Manager when your PC is really chugging away and running very slowly, so you can see which ...

No matter the market environment, you’ll always find entertainment in the biotech space. There will always be biotech stocks ...